PT-141: The First FDA-Approved Peptide for Sexual Health

Bremelanotide (PT 141, marketed as Vyleesi) represents a fundamentally different approach to sexual health pharmacotherapy. While PDE5 inhibitors (sildenafil, tadalafil) work peripherally on vascular smooth muscle to enhance erectile function, bremelanotide is a melanocortin receptor agonist with high affinity for MC4R that is thought to act on brain pathways involved in sexual response (Dhillon et al., 2019, Drugs; PMID: 31429064). This distinction is critical: bremelanotide treats the "wanting," while PDE5 inhibitors treat the "functioning." They address different components of the sexual response cycle (Kingsberg et al., 2019, Obstetrics & Gynecology; PMID: 31599840).

The melanocortin system is a neuroendocrine signaling network involving five receptor subtypes (MC1R through MC5R) and their peptide ligands, primarily alpha melanocyte stimulating hormone (alpha MSH) and related peptides derived from proopiomelanocortin (POMC). This system regulates diverse functions including pigmentation (MC1R), adrenal function (MC2R), energy balance and appetite (MC3R and MC4R), and exocrine function (MC5R). MC4R signaling in the brain is thought to be important for sexual function (Dhillon et al., 2019, Drugs; PMID: 31429064). Largely from animal studies, melanocortins are thought to form part of a hypothalamic and limbic excitatory system for sexual desire that also involves dopamine and oxytocin (Pfaus, 2009, J Sex Med; PMID: 19453889). Researchers studying melanotan II (a tanning peptide) for skin pigmentation noticed that trial participants reported spontaneous sexual arousal as a side effect (Hadley, 2005, Peptides; PMID: 15996790).

Melanotan II is a synthetic cyclic melanocortin analogue that was tested clinically for male erectile dysfunction (Hadley et al., 2006, Peptides; PMID: 16412534). Bremelanotide is a synthetic peptide analogue of alpha MSH with high affinity for the MC4R receptor (Dhillon et al., 2019, Drugs; PMID: 31429064). Bremelanotide was developed as a self administered subcutaneous injection, which proved effective and well tolerated in a Phase IIb dose finding trial in premenopausal women (Clayton et al., 2016, Womens Health (Lond); PMID: 27181790).

Bremelanotide's FDA approval was based on two pivotal Phase III trials, RECONNECT 1 and RECONNECT 2, in premenopausal women with hypoactive sexual desire disorder (HSDD (Kingsberg et al., 2019, Obstet Gynecol; PMID: 31599840)). On the primary endpoint, change from baseline in the Female Sexual Function Index desire domain score, bremelanotide produced statistically significant improvements over placebo (+0.5 points, p < 0.001). It also significantly reduced distress related to low sexual desire as measured by the Female Sexual Distress Scale. Approximately 25% of women treated with bremelanotide reported meaningful improvement in desire, compared to 17% with placebo. That is a modest but statistically significant difference. It is important to set realistic expectations: bremelanotide is not a "magic switch" for desire. It produces a meaningful improvement in a subset of patients, which is consistent with the complexity of sexual desire as a biopsychosocial phenomenon.

On the coprimary endpoint of change from baseline in the Female Sexual Function Index desire domain score, bremelanotide produced statistically significant, though modest, improvements over placebo (integrated difference of 0.35 points) (PMID 31599840). Bremelanotide has been tested in men with erectile dysfunction, but evidence in male sexual dysfunction remains preliminary and it is not approved for use in men (Hellstrom, 2008, Int J Impot Res; PMID: 18552830). As with the FDA approved indication, this is on demand use rather than daily dosing.

The most common side effects in Phase III trials were nausea (40%, the most common reason for stopping), flushing (about 20%), headache (about 11%), and injection site reactions (about 5%); focal hyperpigmentation was rare at labeled dosing but became common with repeated daily dosing (Clayton et al., 2022, J Womens Health (Larchmt); PMID: 35147466)). Bremelanotide can cause small, transient increases in blood pressure, so it should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment (Clayton et al., 2022, J Womens Health (Larchmt); PMID: 35147466). The FDA label limits use to no more than once every 24 hours and no more than 8 doses per month (Mayer et al., 2020, Ann Pharmacother; PMID: 31893927). Bremelanotide can lower plasma concentrations of oral naltrexone and indomethacin, so these interactions should be considered when prescribing (Clayton et al., 2022, J Womens Health (Larchmt); PMID: 35147466).

Bremelanotide (Vyleesi) is given as a 1.75 mg subcutaneous injection (Edinoff et al., 2022, Neurol Int; PMID: 35076581)). It is self administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity (Edinoff et al., 2022, Neurol Int; PMID: 35076581). Providers should set realistic expectations because the clinical benefit may be modest, stop treatment if there is no benefit after 8 weeks, and counsel patients about nausea (Mayer et al., 2020, Ann Pharmacother; PMID: 31893927).

Bremelanotide's approval represents an important milestone: recognition that sexual desire is a legitimate medical concern with neurobiological underpinnings that can be therapeutically targeted. Its central mechanism, working through brain circuits that regulate desire rather than peripheral vascular function, opens a conceptually different approach to sexual health pharmacotherapy. While not a cure all, it provides a genuinely novel option for patients whose primary concern is desire rather than physical arousal or function.